Phase Forward Appoints Michael Owings Chief Privacy Officer

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Michael Owings has been appointed to the newly created role of chief privacy officer. Owings, 55, has held the position of vice president, quality and regulatory compliance at Phase Forward since 2004, and will continue in that related role.

As chief privacy officer, Owings will be responsible for all privacy and data protection policies and best practices affecting Phase Forward’s customers, partners and employees, and ensuring compliance with all relevant regulations. He has been accredited as a Certified Information Privacy Professional through the International Association of Privacy Professionals.

"In his nine years with Phase Forward, Michael has been instrumental in building the company’s reputation as a leader in regulatory compliance,” said Bob Weiler, chairman and CEO of Phase Forward. "This new role is a natural extension of Michael’s in-depth knowledge of compliance issues, and he will help to ensure that our policies and products meet the highest possible standards for processing and storing sensitive data.”

"I look forward to this new role, particularly in light of the challenges customers are facing in an increasingly complex regulatory environment,” said Owings. "My mission is to help ensure that Phase Forward continues to be an expert resource for our customers regarding the latest standards and policies in this fast-changing area.”

Prior to becoming a vice president at Phase Forward, Owings served as director, quality and regulatory affairs from 2002 to 2004, and in other quality affairs and regulatory management roles at the company from 2000 to 2002. Prior to joining Phase Forward, Owings held various positions at Copley Pharmaceutical, at Procept and at Marion Merrell Dow (HMR/Aventis).

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, continued service of its executive personnel and its ability to stay abreast of evolving regulatory standards. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, changes in laws and regulations affecting Phase Forward’s customers and the ability of Phase Forward to retain its executive personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.